| Enrolment | Allocation (trial participants only) | Antenatal period | At hospital discharge |
---|---|---|---|---|
Eligibility screen | x | Â | Â | Â |
Informed e-consent | x | Â | Â | Â |
Baseline EQ-5D | x | Â | Â | Â |
Randomisation and prescription of antihypertensive drug (trial participants only) | Â | X | Â | Â |
Two weeks post enrolment contact (participant completed) | Â | Â | x | Â |
Six weeks post enrolment contact (four weekly thereafter) (participant completed) | Â | Â | x | Â |
Safety reporting (as needed) | Â | Â | x | x |
Case note review (safety and outcome data collection) | x (demographic and clinical baseline data) | Â | x | x |